中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

未开盘 02-25 16:08:35

6.390

+0.000

0.00%

最高6.480	最低6.370	成交量4,635万
今开6.430	昨收6.390	日振幅1.72%
总市值1,199亿	流通市值1,199亿	总股本187.61亿
成交额2.97亿	换手率0.25%	流通股本187.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":6.39,"timestamp":1772006915004,"preClose":6.39,"halted":0,"volume":46354406,"delay":0,"changeRate":0,"floatShares":18761000000,"shares":18761000000,"eps":0.21829819757894242,"marketStatus":"未开盘","change":0,"latestTime":"02-25 16:08:35","open":6.43,"high":6.48,"low":6.37,"amount":296869266,"amplitude":0.017214,"askPrice":6.39,"askSize":426000,"bidPrice":6.38,"bidSize":24000,"shortable":3,"etf":0,"ttmEps":0.24398644639421946,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772069400000},"marketStatusCode":0,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":6.39,"dividendRate":0.014741,"openAndCloseTimeList":[[1771983000000,1771992000000],[1771995600000,1772006400000]],"volumeRatio":1.1797853288201419,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.377,"impliedVolPercentile":0.1707},"requestUrl":"/m/hq/s/01177/tweets","defaultTab":"tweets","newsList":[{"id":"2614508066","title":"每日卖空追踪 | 中国生物制药 02月25日卖空量成交742.5万股，卖空比例为16.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614508066","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614508066?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:30","pubTimestamp":1772008221,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间02月25日，股价较前一交易日持平，卖空量成交742.5万股，较上一交易日减少78.39%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163224a4c6731d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163224a4c6731d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1589","BK1515","BK1521","01177","BK1191","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2613710423","title":"中国生物制药02月24日主力净流出3665.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2613710423","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613710423?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:15","pubTimestamp":1771920957,"startTime":"0","endTime":"0","summary":"02月24日, 中国生物制药股价跌6.58%，报收6.39元，成交金额5.9亿元，换手率0.49%，振幅6.14%，量比3.50。中国生物制药今日主力资金净流出3665.4万元，上一交易日主力净流入792.1万元。该股近5个交易日上涨2.28%，主力资金累计净流出3599.1万元；近20日主力资金累计净流出9655.5万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224162137a4c22791&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224162137a4c22791&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","IE00BZ08YT58.USD","BK1589","BK1191","BK1521","IE00BZ08YS42.EUR","01177","IE00BZ08YR35.GBP","HK0000165453.HKD"],"gpt_icon":0},{"id":"2613771023","title":"再加码，中国生物制药1类创新药迎来新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2613771023","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613771023?lang=zh_cn&edition=full","pubTime":"2026-02-24 08:00","pubTimestamp":1771891219,"startTime":"0","endTime":"0","summary":"近日，2026年2月14日，据中国国家药品审评中心官网显示，中国生物制药旗下北京泰德制药股份有限公司按化药注册分类1类申报的TCR1672缓释片临床试验申请获默示许可。此次，TCR1672缓释片获批临床，可谓是该款新药从普通片到缓释片的再加码。P2X3受体在神经系统和呼吸系统中广泛表达，与慢性咳嗽等疾病密切相关。希望北京泰德制药的TCR1672缓释片后续相关临床试验顺利推进，早日为广大患者提供更多的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224081918a7175cac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224081918a7175cac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","06978","IE00BZ08YR35.GBP","BK1515","BK1521","BK1191","BK1574","BK1161","IE00BZ08YT58.USD","BK1589","01177","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2613178781","title":"每日卖空追踪 | 中国生物制药 02月23日卖空量成交344.7万股，卖空比例为11.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613178781","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613178781?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:30","pubTimestamp":1771835419,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间02月23日，涨2.86%，卖空量成交344.7万股，较上一交易日减少45.57%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163207a7156339&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163207a7156339&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","01177","BK1515","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1589","HK0000165453.HKD","BK1191","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2613378786","title":"中国生物制药盘中异动 早盘股价大涨3.01%报6.850港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613378786","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613378786?lang=zh_cn&edition=full","pubTime":"2026-02-23 10:00","pubTimestamp":1771812023,"startTime":"0","endTime":"0","summary":"2026年02月23日早盘10时00分，中国生物制药股票出现异动，股价快速上涨3.01%。截至发稿，该股报6.850港元/股，成交量670.28万股，换手率0.04%，振幅2.86%。资金方面，该股资金流入2983.38万港元，流出899.442万港元。中国生物制药股票所在的药品行业中，整体涨幅为0.66%。其相关个股中，中国同辐、九源基因、中国生物制药涨幅较大，振幅较大的相关个股有泰德医药、精优药业、中国同辐，振幅分别为9.85%、8.33%、6.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223100024a71478f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223100024a71478f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YT58.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","01177","BK1515","BK1191","BK1589","HK0000165453.HKD","BK1521"],"gpt_icon":0},{"id":"2612629452","title":"每日卖空追踪 | 中国生物制药 02月20日卖空量成交287.2万股，卖空比例为13.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612629452","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612629452?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:30","pubTimestamp":1771576219,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间02月20日，涨1.84%，卖空量成交287.2万股，较上一交易日减少14.47%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163219a4b5e74e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163219a4b5e74e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1589","01177","IE00BZ08YT58.USD","BK1191","BK1515","BK1521"],"gpt_icon":0},{"id":"2612252506","title":"IO2.0争夺战打响，下一代肿瘤“药王”花落谁家？","url":"https://stock-news.laohu8.com/highlight/detail?id=2612252506","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612252506?lang=zh_cn&edition=full","pubTime":"2026-02-20 15:00","pubTimestamp":1771570819,"startTime":"0","endTime":"0","summary":"下一代肿瘤“药王”争夺战打响！撰文丨粽哥2025下一代肿瘤“药王”，极有可能诞生于PD-1+X领域。以K药为代表的PD-1单抗，开启了一代IO治疗时代，但却存在耐药和冷肿瘤缺乏应答的问题。临床上，T细胞耗竭现象是导致免疫检查点获得性耐药的关键机制。TIGIT是经典免疫逃逸靶点，在多种淋巴细胞上表达，被认为是“下一个PD-1”。不过，PD-1/TIGIT双抗或有望打破TIGIT“难以成药”的魔咒。TIGIT和PD-1表达之间存在很强的相关性，特别是在肺癌的肿瘤浸","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602201513389541818d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602201513389541818d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B543WZ88.USD","LU2476274720.SGD","09887","LU0348767384.USD","01877","LU0348766576.USD","02898","02616","01530","LU0348783233.USD","LU0561508036.HKD","LU2399975544.HKD","LU0417516902.SGD","LU2488822045.USD","LU1961090484.USD","09995","LU2778985437.USD","01801","LU0348827113.USD","LU0417516571.SGD","LU0540923850.HKD","LU1720050803.USD","09926","LU0634319403.HKD","IE00B5MMRT66.SGD","BK1161","LU0417516738.SGD","LU0348784397.USD","02696","LU2476274308.USD","LU1794554557.SGD","LU0348825331.USD","IE00BPRC5H50.USD","BK1574","LU0348735423.USD","01177"],"gpt_icon":1},{"id":"2611107186","title":"每日卖空追踪 | 中国生物制药 02月16日卖空量成交335.8万股，卖空比例为42.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611107186","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611107186?lang=zh_cn&edition=full","pubTime":"2026-02-16 16:30","pubTimestamp":1771230617,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间02月16日，涨0.15%，卖空量成交335.8万股，较上一交易日减少68.94%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163155a700dde6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163155a700dde6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1191","BK1515","HK0000165453.HKD","BK1521","BK1589","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2611101033","title":"中国生物制药02月16日获主力加仓136.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611101033","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611101033?lang=zh_cn&edition=full","pubTime":"2026-02-16 16:15","pubTimestamp":1771229733,"startTime":"0","endTime":"0","summary":"02月16日, 中国生物制药股价涨0.15%，报收6.53元，成交金额5077.3万元，换手率0.04%，振幅1.99%，量比0.18。中国生物制药今日主力资金净流入136.1万元，上一交易日主力净流入193.9万元。该股近5个交易日下跌1.06%，主力资金累计净流入2153.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1.1亿元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216161708a4a9ed1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216161708a4a9ed1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1521","01177","BK1191","BK1515","HK0000165453.HKD"],"gpt_icon":0},{"id":"2611793561","title":"中国生物制药(01177)：贝莫苏拜单抗注射液非小细胞肺癌放化疗后维持适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2611793561","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611793561?lang=zh_cn&edition=full","pubTime":"2026-02-16 06:39","pubTimestamp":1771195149,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团自主研发的国家1类创新药贝莫苏拜单抗新适应症已获得中国国家药品监督管理局 的上市批准，用于在接受铂类药物为基础的同步或序贯放化疗后未出现疾病进展的未携带已知表皮生长因子受体敏感突变或间变性淋巴瘤激酶重排的不可切除III期非小细胞肺癌 患者的治疗。贝莫苏拜单抗是中国第三款获批用于局部晚期╱不可切除NSCLC根治性放化疗后巩固治疗的PD-L1 抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药(01177)：贝莫苏拜单抗注射液非小细胞肺癌放化疗后维持适应症获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","IE00BZ08YR35.GBP","BK1191","01177","BK1521","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","HK0000165453.HKD","BK1589"],"gpt_icon":0},{"id":"2610948974","title":"美银证券：中国生物制药(01177)两款药物进度积极 重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2610948974","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610948974?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:18","pubTimestamp":1770884292,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，中国生物制药(01177)两款药物TQB2102及LM302近期已完成第三期临床研究的受试者入组。当中LM302是全球首个完成第三期注册性临床研究受试者入组的CLDN18.2抗体药物复合体，有望为患者提供新的治疗选择。该行现予目标价8.6港元，重申“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","01177"],"gpt_icon":0},{"id":"2610919168","title":"国联民生证券：小核酸重构减肥逻辑 INHBE与ALK7靶点初步验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2610919168","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610919168?lang=zh_cn&edition=full","pubTime":"2026-02-12 14:27","pubTimestamp":1770877647,"startTime":"0","endTime":"0","summary":"小核酸减肥靶点主要有INHBE靶点、ARO-ALK7靶点以及靶向肌肉的GeneD靶点三个，中国药企在小核酸减肥适应症的布局速度几乎与海外药企同步。国联民生证券主要观点如下：Arrowhead公布两款小核酸药物的初步减肥疗效良好Arrowhead公司公布了两个靶点INHBE和ALK7的小核酸药物的减肥效果，展现出良好的初步疗效：ARO-INHBE精准减脂：脂肪平均减少9.9%，肝脏脂肪减少幅度高达38.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601456","IE00BVYPNQ40.USD","SG9999015978.USD","IE00BVYPNP33.GBP","HK0000165453.HKD","BK1564","LU1023057109.AUD","BK1589","00867","LU0359201885.HKD","SG9999015945.SGD","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","LU0359202008.SGD","LU2488822045.USD","SG9999015986.USD","SG9999015952.SGD","IE00BYV24P56.USD","01456","BK1191","BK1515","SG9999004220.SGD","LU2543165471.USD","BK1147","BK1593","161027","IE00BZ08YT58.USD","01276","IE00BZ08YR35.GBP","BK1521","BK0276","IE00BZ08YS42.EUR","LU0359201612.USD","01177"],"gpt_icon":0},{"id":"2610641826","title":"正大天晴（中国生物制药）深度调研报告：创新转型的跨越与全球化征途的破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2610641826","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610641826?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:31","pubTimestamp":1770712268,"startTime":"0","endTime":"0","summary":"正大天晴作为中生制药最为核心的附属公司，贡献了集团绝大部分的营收与利润，其实质运营状况直接决定了上市主体的二级市场表现与长期价值。这种“引进来”与“走出去”的双向流动，标志着正大天晴已具备参与全球医药创新产业链分工的能力。2024年，肿瘤药物销售额约107.3亿元，占总营收比重达37.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163542a6e9af5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163542a6e9af5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","HK0000165453.HKD","IE00BZ08YT58.USD","BK1515","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","01177","BK1191","BK1521"],"gpt_icon":0},{"id":"2610622038","title":"每日卖空追踪 | 中国生物制药 02月10日卖空量成交1026.2万股，卖空比例为12.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610622038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610622038?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:30","pubTimestamp":1770712220,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间02月10日，涨2.88%，卖空量成交1026.2万股，较上一交易日减少32.39%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163231a6e9ab81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163231a6e9ab81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1521","BK1515","01177","BK1191","HK0000165453.HKD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2610969486","title":"创新药概念震荡反弹 高增长潜力概念股出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2610969486","media":"腾讯自选股综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610969486?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:17","pubTimestamp":1770693474,"startTime":"0","endTime":"0","summary":"创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。华源证券指出，经历短期波动消化后，创新药板块已显现企稳回暖迹象。整体上，国金证券认为创新药前期回调较为充分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。从未来增长潜力来看，多股获机构预测2026年净利增速有望翻倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","02196","00013","01548","BK1161","02096","01276","01877","BK1574","06978","02269","01177","01093","02228","03692","BK1583","01952","01513","BK1515","00512","06185","06160","01801"],"gpt_icon":0},{"id":"2610699154","title":"中国生物制药(01177)升5% TQB2102 III期临床完成入组 此前Ib期ASCO数据良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2610699154","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610699154?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:52","pubTimestamp":1770691959,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药(01177)短线拉高，截止发稿， 升5.15%，报6.94港元，成交额1.94亿港元。公司公告公布，集团自主研发的国家1类创新药TQB2102“HER2双抗ADC”正在开展一项“评价注射用TQB2102对比研究者选择的化疗在HER2低表达复发╱转移性乳腺癌中有效性和安全性的随机、开放、平行对照的III期临床试验(TQB2102-III-01)”，近期已完成全部受试者入组。在2025年美国临床肿瘤学会(ASCO)年会上，集团公布了TQB2102用于HER2低表达晚期乳腺癌的 Ib期临床研究结果，显示出良好的疗效与安全性。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974849","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK4134","IE00BZ08YR35.GBP","BK1191","01177","BK1521","III","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","HK0000165453.HKD","BK1589"],"gpt_icon":0},{"id":"1181610865","title":"异动解读 | 乳腺癌药物III期临床试验完成受试者入组，中国生物制药盘中大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181610865","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181610865?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:41","pubTimestamp":1770691267,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中大涨5%，引起了市场的广泛关注。消息面上，公司自主研发的国家1类创新药TQB2102“HER2双抗ADC”用于治疗HER2低表达复发/转移性乳腺癌的III期临床试验，近期已完成全部受试者入组。TQB2102是公司自主研发的新一代抗体偶联药物，采用了双表位靶向设计、可裂解连接子及优化的药物抗体比等核心技术，旨在为HER2低表达乳腺癌患者提供新的治疗选择。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"2610615985","title":"中国生物制药盘中异动 大幅拉升3.03%报6.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610615985","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610615985?lang=zh_cn&edition=full","pubTime":"2026-02-10 09:48","pubTimestamp":1770688118,"startTime":"0","endTime":"0","summary":"2026年02月10日早盘09时48分，中国生物制药股票出现异动，股价急速上涨3.03%。截至发稿，该股报6.800港元/股，成交量614.025万股，换手率0.03%，振幅3.03%。资金方面，该股资金流入2579.63万港元，流出1043.47万港元。中国生物制药股票所在的药品行业中，整体涨幅为0.55%。其相关个股中，英硅智能、劲方医药-B、德琪医药-B涨幅较大，振幅较大的相关个股有英硅智能、宝济药业-B、劲方医药-B，振幅分别为8.41%、7.25%、5.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210094838954081f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210094838954081f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","BK1515","BK1589","BK1191","IE00BZ08YS42.EUR","01177","HK0000165453.HKD","BK1521","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2610661036","title":"中国生物制药(01177)：TQB2102“HER2双抗ADC”HER2低表达乳腺癌III期临床试验完成受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2610661036","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610661036?lang=zh_cn&edition=full","pubTime":"2026-02-10 06:16","pubTimestamp":1770675411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团自主研发的国家1类创新药TQB2102“HER2双抗ADC”正在开展一项“评价注射用TQB2102对比研究者选择的化疗在HER2低表达复发╱转移性乳腺癌中有效性和安全性的随机、开放、平行对照的III期临床试验”，近期已完成全部受试者入组。以上核心技术的结合，突破了传统HER2单抗及单靶点ADC的局限，使TQB2102在HER2低表达肿瘤治疗中展现出显著潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","ADC","III","BK4080","BK1191","IE00BZ08YR35.GBP","BK1515","HK0000165453.HKD","01177","BK1589","BK4134","IE00BZ08YT58.USD","BK4231","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2610615938","title":"每日卖空追踪 | 中国生物制药 02月09日卖空量成交885.6万股，卖空比例为17.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610615938","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610615938?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:30","pubTimestamp":1770625819,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间02月09日，涨1.85%，卖空量成交885.6万股，较上一交易日减少52.02%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163601a6e54dae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163601a6e54dae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YT58.USD","BK1589","BK1191","01177","IE00BZ08YR35.GBP","BK1515","BK1521"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.1},{"period":"6month","weight":-0.2121},{"period":"1year","weight":0.9399},{"period":"ytd","weight":0.034}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0},{"period":"3month","weight":0.0316},{"period":"6month","weight":0.0673},{"period":"1year","weight":0.162},{"period":"ytd","weight":0.0443}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.008254},{"month":2,"riseRate":0.652174,"avgChangeRate":0.058913},{"month":3,"riseRate":0.590909,"avgChangeRate":0.048254},{"month":4,"riseRate":0.5,"avgChangeRate":0.025891},{"month":5,"riseRate":0.727273,"avgChangeRate":0.043347},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.01175}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}